Editas Medicine Inc (EDIT)

Jun 19, 2025

Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com

Jun 19, 2025

Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025

Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com

Jun 17, 2025

Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025

Jun 17, 2025

Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

Jun 17, 2025

Jun 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat

Jun 14, 2025

Jun 14, 2025

Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat

Jun 14, 2025

Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 13, 2025

Jun 12, 2025

Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus

Jun 12, 2025

Jun 12, 2025

Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media

Jun 12, 2025

Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus

Jun 12, 2025

Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus

Jun 12, 2025

Jun 12, 2025

Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq

Jun 12, 2025

Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times

Jun 12, 2025

Jun 12, 2025

Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan

Jun 12, 2025

Jun 11, 2025

Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance

Jun 11, 2025

Jun 09, 2025

Ameriprise Financial Inc. Has $289,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 09, 2025

Jun 08, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock - MarketBeat

Jun 08, 2025

Jun 07, 2025

Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat

Jun 07, 2025

Jun 05, 2025

Two Sigma Investments LP Increases Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 05, 2025

Jun 05, 2025

Millennium Management LLC Has $3.49 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 05, 2025

Jun 04, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in May - MarketBeat

Jun 04, 2025

Jun 02, 2025

editas medicine amends stock plan and increases authorized shares - Investing.com

Jun 02, 2025

Jun 02, 2025

Editas Medicine Stockholders Approve Key Amendments - TipRanks

Jun 02, 2025

Jun 02, 2025

editas medicine amends stock plan and increases authorized shares By Investing.com - Investing.com India

Jun 02, 2025

Jun 01, 2025

Two Sigma Advisers LP Increases Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 01, 2025

Jun 01, 2025

Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io

Jun 01, 2025

May 31, 2025

Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 31, 2025

May 30, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 30, 2025

May 30, 2025

Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 30, 2025

May 28, 2025

Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

May 28, 2025

May 28, 2025

Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus

May 28, 2025

May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025

May 28, 2025

CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com

May 28, 2025

May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada

May 26, 2025

May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia

May 26, 2025

May 25, 2025

1 Stock Down 97% That Could Double, According to Wall Street - AOL.com

May 25, 2025

May 24, 2025

Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 24, 2025

May 23, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World

May 23, 2025

May 22, 2025

Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 22, 2025

May 21, 2025

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st

May 21, 2025